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ABSTRACT 
 
Austin Heath Carroll: Assembly of a Protein-based Hydrogel as a Vehicle for In Situ 
Drug Delivery (Under the direction of Dr. Susan Pedigo)  
 
 
The goal of this work is to develop a self-assembling, protein-based gel to deliver 
drugs at the site of chronic inflammation. There are two engineered protomers that 
comprise the gel; calmodulin- and M13- are their critical components. Numerous 
enzymes have been shown to undergo calcium-dependent regulation by calmodulin, an 
intracellular protein highly resilient to its chemical environment. One of these enzymes, 
myosin light chain kinase, contains a remarkable 26 residue portion known as the M13 
peptide that has been demonstrated to bind to calmodulin in the presence of calcium 
through hydrophobic interactions. Because the extracellular space in vivo constitutes an 
environment rich in calcium, mixtures of engineered proteins with M13 (called PMSP) 
and calmodulin (called CMSP) will form a network. These engineered protein mixtures 
can be functionalized with drugs for delivery to the extracellular space at sites of chronic 
inflammation. This two component binding system can be tuned to modify the affinity 
and cooperativity with which self-assembly occurs, thus making it the perfect vehicle for 
in situ drug delivery. The purpose of the work reported here is to study the M13 peptide-
containing protomer, PMSP. Since this is a novel construct, this thesis reports basic 
studies of the bacterial expression, solubility, interactions with calmodulin, and evidence 
that it forms a gel with CMSP. In order to obtain PMSP sufficient for hydrogel formation, 
we have bacterially expressed the protein. We have found PMSP to express poorly, with 
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yields increased upon expression from freshly transformed cells. Further, PMSP has 
limited solubility in aqueous solutions, requiring the addition of Guanidine HCl or 
DMSO to solubilize it. Once in solution, we found that the aqueous solubility of PMSP 
increased in the presence of free calmodulin implying that PMSP bound calmodulin. 
Secondly, PMSP appeared to bind to CMSP in the presence of calcium and to form a 
viscous solution. We are actively working to develop spectroscopic methods to support 
the apparent calmodulin-PMSP binding data. Finally, we will report our first attempts to 
measure the viscosity of the PMSP and CMSP mixture. 
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INTRODUCTION 
 
Inflammation is a critical response to injury or infection that provides the body 
with the ability to destroy pathogenic invaders and to repair damaged tissues 1. During 
these acute periods, inflammation increases blood flow and recruits immune cells to the 
point of grievance leading to pain and swelling 2. This inflammatory process is sequential 
with checkpoints in place to ensure that immune cell recruitment, microbe destruction, 
tissue liquefaction, and tissue repair occur in the correct order 3. When this sequential 
process is disrupted, a holding pattern known as chronic inflammation occurs. While 
acute inflammation promotes tissue repair, chronic inflammation in diseases such as 
cancer, diabetes, cardiovascular disease, endometriosis, sciatic nerve pain and various 
autoimmune disorders 4 actually further damages tissues and oxidizes DNA 3. Chronic 
inflammation also causes local acidification in the tissues 5 and the release of matrix 
metalloproteinases that remodel the extracellular space 6. Treatment is necessary to 
circumvent and combat the destructive aspects of chronic inflammation.  
 The most common treatment for chronic inflammation is the use of non-steroidal 
anti-inflammatory drugs (NSAIDS) like aspirin, acetaminophen, and ibuprophen 7. These 
drugs must be administered orally or intravenously, however, and are systemically 
distributed to all tissues. This systemic distribution leads to toxicity in the liver, kidneys, 
and GI tract. Over periods of chronic use, or as a result of extreme dosage, this collateral 
damage leads to organ failure 8. The purpose of our system is thus to create an injectable, 
protein-based hydrogel capable of self-assembly in vivo that will bioconjugate with 
NSAIDs to deliver them to the extracellular space in a controlled manner. By 
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accomplishing this task, we will help circumvent the issue of NSAID toxicity and will 
provide a method for controlling chronic inflammation. As this system is developed, it is 
highly probable that the hydrogel will be useful in delivering other types of drugs as well. 
 Our protein-based hydrogel exploits the binding properties of two intracellular 
proteins: calmodulin (CaM) and M13. Calmodulin is an acidic, 148 residue amino acid 
protein that acts as a calcium-dependent regulator in a number of intracellular processes 
(Figure 2a) 9. These processes range from signal transduction pathways involving the 
calmodulin-Ca2+ kinases (CaMK I-VI), AMPA receptor recycling in neurons 10, and 
smooth muscle contraction in an interaction with a specific portion of myosin light chain 
kinase (MLCK) 11. This highly specific interaction of CaM with MLCK is the basis of the 
interactions between the protomers in our hydrogel (Figure 1). As CaM binds M13, the 
previously unstructured M13 peptide assumes a helical shape, and the CaM protein 
becomes more compact 12. 
 
 
 
 
 
 
Figure 1. Calmodulin – Peptide Interaction: CaM (depicted in blue) binds tightly 
to a 26 amino acid portion of the enzyme myosin light chain kinase (depicted in red) 
when in the presence of calcium. When this binding occurs, the peptide develops a 
helical shape from a previously unstructured state while calmodulin becomes more 
compact. 
 
3	
	
MLCK is an enzyme present in smooth muscle that contains a 26 amino acid 
sequence known as M13 (Figure 2b). This M13 sequence is critical for calcium 
dependent muscle contraction. As calcium enters the cellular cytoplasm, it binds to CaM 
(Kd = ~1 µM C-terminus, Kd = ~10 µM N-terminus), which then binds to the M13 portion 
of MLCK resulting in muscle contraction 13. This binding occurs through hydrophobic 
interactions with very high affinity (Kd = < 10 nM) and is the basis for the formation of 
our hydrogel 14. Because calcium is present in much greater concentrations in the 
extracellular space than inside the cytoplasm, our calmodulin-based component will be 
saturated with calcium and capable of binding the M13 component when injected into the 
extracellular space.  
 
 
 
 
 
 
 
 
Figure 2a: Calmodulin’s structure, properties, and amino acid sequence 
Ribbon drawing of calmodulin and AA sequence: Ribbon drawing of calmodulin with 
calcium binding sites shown in yellow.  Helices lead into and out of each site.  The “central helix” separates 
two independently folded domains.  When calcium binds, hydrophobic surface area is exposed at the base of 
each pair of sites. 
 
Figure 2b: M13’s structure, properties, and amino acid sequence 
Ribbon drawing of M13 and AA sequence: Ribbon drawing of M13 demonstrating the 
peptide’s inherent lack of structure. As binding with calmodulin occurs through hydrophobic interactions, 
however, the peptide assumes a helical structure. 
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PROTEIN DESIGN 
 
Description of Protomers 
 
 
Our experimental design makes use of two protomers derived from bacterially 
expressed, synthetic genes: one containing M13 and the other containing CaM. The M13-
based protomer (PMSP for Peptide-Modification-Sequence-Protein) is the primary focus 
of this thesis and involves two repeats of M13 separated by “two cleavable modification 
sequences” (Figure 3). These modification sequences are similar to collagen and are sites 
for degradation by matrix metalloproteinases that are present in the extracellular space 
and increasingly secreted during times of inflammation 6. PMSP also contains a 6-
histidine sequence for Histag purification as well as a cysteine residue on the C-terminus 
that allows for the formation of a disulfide linkage to another PMSP in oxidizing 
conditions. The two repeats of M13 within the protomer provide high affinity binding 
sites for the calmodulin-based protomer when in the presence of calcium. The 
calmodulin-based protomer (CMSP) is nearly identical to PMSP and contains two 
sequences of CaM separated by two collagen-like sequences. Like the PMSP component, 
it also contains a 6-histidine sequence on the N-terminus for purification and a terminal 
cysteine on the C-terminus for creating a disulfide linkage with identical protomers 
(Figures 3a and 3b). 
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Hydrogel Design 
 
 
Our design makes use of the inherent properties of a hydrogel, which is a 3D 
network of crosslinked polymers that retain high amounts of water and demonstrate 
elasticity and strength similar to bodily tissues 15. Through the use of biomaterials 
capable of binding in response to extracellular calcium, our hydrogel will self-assemble 
and respond to inflammation. Through a collaborative project with the Watkins lab, we 
will bioconjugate NSAIDs to the calmodulin protomer through ester linkages, and the gel 
will respond to the increased acidity in the extracellular space during times of 
inflammation. As the pH decreases, the ester linkages will be hydrolyzed and the drug 
will be increasingly delivered. Degradation of the gel by proteases and consequent drug 
release will also be further accelerated by the increased release of matrix 
metalloproteinases during times of inflammation. As needed, the composition, size, and 
Figure 3a: CMSP and PMSP Constructs 
Depictions of CMSP and PMSP: Each protomer contains a Histag sequence depicted in green and 
black, two repeats of CaM or M13, two repeats of a collagen—like sequence (CLS), and a terminal 
cysteine.  
Figure 3b: Formation of Protomer Dimers 
Depiction of Dimer Formation 
Under oxidizing conditions, the C-terminus cysteine residues allow the protomers to form disulfide 
linkages. This allows for the formation of four binding sites on each of the constructs. 
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drug dosage of the hydrogel can be modified, making it the perfect vehicle for in situ 
drug delivery. 
 
Structure of the Thesis 
 
 
 Since PMSP is a completely novel protein, there is no precedence for its 
properties. As we worked with this engineered protein, we encountered a number of 
unexpected results that then drove the next steps. We present this “odyssey” as it 
unfolded, and while the story is still developing, this thesis documents the path so far. 
 
 
SCOPE OF WORK 
  
To obtain PMSP, we transformed BL21DE3 Rosetta cells with a pET30 plasmid 
containing our gene that confers kanamycin resistance (Figure 4a). By growing our cells 
on agar plates spiked with kanamycin, we were able to successfully confirm that 
transformation occurred. IPTG, a molecular mimic of allolactose, a lactose metabolite 
that triggers transcription of the lac operon, was then used to induce bacterial expression 
of our protein. After expression, the cells were centrifuged, sonicated and centrifuged 
once more (Figure 4b). An acrylamide gel was then used to demonstrate that PMSP was 
present in the post-induction pellet and in the sonicated whole cell but not in the post- 
induction supernatant (Figure 5a). This important piece of data revealed that PMSP is 
not soluble in aqueous solutions. This forced us to recover it from the pellet. Thus, the 
pellet was treated with Triton-X, a non-ionic surfactant capable of permeabilizing cell 
membranes. Three washes were carried out with an initial wash using 10% Triton-X and 
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two subsequent washes using 1% Triton-X. Each wash was followed by centrifugation. 
Samples were taken before and after each wash, and after centrifugation for an SDS-
acrylamide gel (Figure 5b), which demonstrated that the protein remained in the pellet 
after the 10 % TX and 1% TX washes. 
In order to solubilize the pellet, we tried several strategies. First, in previous work 
from our lab, Christopher Fox showed that the PMSP was not adequately solubilized in 
concentrated urea. Thus, 6 M Guanidine HCl/20 mM Tris/ 140 mM NaCl/pH 7.4 was 
added to the pellet. After significant vortexing, the pellet was dislodged and mixed with 
the aqueous solvent. At this point, a large gelatinous material descended to the bottom of 
the conical (Figure 6b), and we speculated that it could be DNA based on its appearance. 
This gel was mechanically removed, washed with distilled water three times, and was 
then sonicated for 30 seconds and centrifuged for 30 minutes at 3000 rpm. An SDS-
acrylamide gel was run to evaluate the protein in the supernatant and gel portions of the 
gelatinous material (Figure 5c). A subsequent UV spectrum was also taken of the 
supernatant but due to scattering of light by insoluble material, no clear signal could be 
obtained.  
The Triton-X, Guanidine-treated supernatant was then taken into 1 mL aliquots, 
centrifuged for 8 minutes and placed on a Histag column equilibrated with Binding 
Buffer + 6 M Guanidine. Wash buffers and elution buffers also containing 6 M 
Guanidine were used to maintain protein solubility through the entire separation. 
Subsequently, an acrylamide gel and UV-Vis spectrum revealed that PCLP had been 
successfully purified for the first time (Figure 5d and Figure 6a), but that it had low 
solubility in aqueous buffers.  There were two elution fractions with PMSP with 
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concentrations of ~ 40 µM and 100 µM. Studies described in this thesis were conducted 
with the 40 µM fraction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4a: Transformation and Induction of BL21D3 
Rosetta Cells 
Depiction of PMSP designed plasmid followed by 
transformation and induction: The PMSP gene 
contains a sequence for kanamycin resistance and a 
lac operon site for the induction of expression using 
IPTG 
Figure 4b: Flow Chart of Transformation, 
Expression, and Recovery  
Establishing a cell stock, expressing PMSP, and 
Purification: The protocol for PMSP purification 
requires transformation of BL21D3 cells, cell 
reproduction in liquid cultures, and purification using 
Triton X and Guanidine. 
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Figure 5a: Acrylamide gel demonstrating initial expression and sonification of PMSP 
Post induction sample and sonicated whole cell: After induction with IPTG, the gel revealed that PMSP was 
present at 18 kD in both the post induction sample and the sonicated whole cell sample. This indicates that PMSP 
is not soluble in aqueous solution 
Figure 5b: Gel demonstrating 10% and 1% triton-X washes to PMSP pellet 
Triton-X Wash samples: After each subsequent round of washing with Triton-X, the gel revealed that PMSP 
remained confined to the pellet further indicating insolubility 
Figure 5c: Gel demonstrating TX and Guanidine treatment to PMSP Pellet and analysis of gelatinous component 
Guanidine Treatment and gelatinous material analysis: Treatment with guanidine allowed the PMSP to move 
into solution as shown in the gel. The gelatinous material was also demonstrated to contain PMSP. 
Figure 5d: Gel demonstrating final purification of PMSP through Histag chromatography 
Histag Chromatography Purification: Histag purification using binding, wash, and elution buffers containing 6 
M Guanidine led to the purification of PMSP. Material visualized below 18 kD shows truncated products. 
 
Figure 6a: UV-Vis Spectrum Demonstrating the Purification of PMSP 
Figure 6b: Gelatinous material that was Mechanically Removed from PMSP after the addition of 6 M 
Guanidine 
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Solubility Tests 
 
 
 Through the expression and purification of PMSP, we have determined it is 
largely insoluble in aqueous solution. It was thus necessary to carry out several solubility 
tests to determine feasible solvents for mixtures with CMSP. The first test included 
dialyzing a portion of PMSP stock out of aqueous guanidine and into pure DMSO. 
Through this transition, the PMSP remained fully soluble, and it was determined that 
DMSO was a feasible solvent for working with our protein.  
The second test consisted of dialyzing a portion of PMSP into 100 mL solutions 
of aqueous SEC buffer consisting of HEPES and NaCl with gradually decreasing 
amounts of guanidine. The solutions ranged from 6 M, 4.5 M, 3 M, 1.5 M, and 0.5 M 
guanidine. Each solution was dialyzed for approximately an hour. The PMSP remained 
fully soluble until the transition from 2 M to 0.5 M guanidine. At this point, the protein 
formed a heavy, white precipitate. Interestingly, no gelatinous material reformed.  
Next, we hypothesized that the addition of hydrophilic CaM would increase the 
aqueous solubility of PMSP. To this end, 3 mg of dry CaM and concentrated aqueous 
calcium to a concentration of 1 mM were added to the precipitated solution. These two 
additions did not bring the precipitated PMSP back into solution. This mixture was 
dialyzed into 200 mL of 2 M guanidine/20 mM HEPES/ 140 mM NaCl/pH 7.4 (SEC 
buffer) for one hour and the protein returned into solution. After this, the solution was 
dialyzed into 200 mL of pure SEC buffer for 2 hours. This time, the protein remained 
fully soluble in the aqueous SEC solution (Figure 7). This indicates that 1) PMSP binds 
to CaM in the presence of calcium, and that 2) the binding of CaM to PMSP increases the 
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solubility of PMSP. 
 
 
 
 
 
  
 
 
 
 
 
After testing PMSP alone and in the presence of CaM, we tested the solubility of 
PMSP in the presence of the CMSP protomer. This was accomplished by adding 5 mg of 
dry CMSP to 1.5 mL of 40 µM PMSP in 6 M guanidine and dialyzing it against aqueous 
SEC buffer. After an hour, an extremely white, heavy precipitate formed and the solution 
was dialyzed into a 2 M guanidine solution. This allowed the protein to return to solution. 
Finally, the solution was dialyzed against pure DMSO, and the CMSP/PMSP mixture 
remained soluble. 
Figure 7: Solubility Schematic of PMSP in SEC Buffer with varying Concentrations of Guanidine 
Decreasing Guanidine Decreases Solubility but adding CaM and Ca2+ Increases Solubility: 
As the concentration of guanidine is decreased, solubility decreases. At 0.5 M guanidine, PMSP 
precipitates out of solution. As demonstrated, when CaM and Ca2+ are added, PMSP remains 
fully soluble in aqueous SEC buffer. This indicates that PMSP is binding CaM.  
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Formation of a Hydrogel 
 
 
 In order to form our first hydrogel, we concentrated the CMSP/PMSP mixture in 
DMSO to 113 µM PMSP and 225 µM CMSP and added calcium to a final concentration 
of approximately 50 mM. Within five minutes, the solution became turbid and took upon 
the appearance of a viscous gel (Figure 8c).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8a: Decreasing Guanidine Concentrations Reduces PMSP Solubility 
Dialysis Experiment Reducing Guanidine Concentration: Dialysis bags, shown between green 
clamps, demonstrate decreased solubility as guanidine is removed. Left, PMSP is soluble in 6 M 
guanidine but forms a cloudy precipitate in 0.5 M guanidine.  
Figure 8b: Adding CaM and Ca2+ solubilizes PMSP in SEC Buffer 
Dialysis Experiment with the Addition of CaM and Ca2+: After the addition of CaM and Ca2+, 
PMSP becomes fully soluble in aqueous solution. Left, a cloudy precipitate is present in SEC buffer. 
Right, PMSP is solubilized in SEC after the addition of CaM and Ca2+. 
Figure 8c: Formation of our First Hydrogel 
Combining PMSP and CMSP Protomers in the presence of Ca2+: Upon mixing both protomers 
in high concentration in DMSO and adding calcium, a viscous and gel-like material formed. 
 
50 mM Ca2+  
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Synthetic Peptide Alternative 
 
 
         As a possible alternative for circumventing the solubility issue of the PMSP 
protomer, we also designed a short 48 amino acid peptide with the following sequence: 
CGGSSKRRWKKNFIAVSAANRFKKISSSGALGSREGPQGIWGQERSGC (The 26 
residue M13 sequence is in bold and the collagenase cleavage sequence is underlined. 
Cysteines are at the termini). To synthesize the peptide, we used a CEM peptide 
synthesizer in the lab of Dr. Saumen Chakraborty with the help of Dr. Chakraborty and 
Suchitra Mitra. This peptide contains the full M13 sequence and only a single collagen-
like modification sequence to increase solubility. Cysteines are present at each end to 
allow linkages of the peptide segments into protomers with a diversity of lengths and 
geometries. Just after synthesis, the peptide was cleaved from the bead, and a MALDI-
TOF mass was obtained of the peptide product.  The mass spectrum demonstrated an 
envelope of products ranging from a mass of 4.8 kD to 5.7 kD (Figure 9a), a range that 
spans the expected molecular weight (5.1 kD). We are not clear as to what the envelope 
of products indicates, although we have speculated that truncated products and impurities 
are present in the sample. Upon analysis with an acrylamide gel using samples with BME 
reducing loading buffer in DMSO and SEC solutions and a sample with non-reducing 
loading buffer in SEC solution, bands were visualized at approximately 10 kD (Figure 
9b). This size is the expected weight of peptide dimers, although it is unclear why 
polymerization occurred regardless of whether or not reducing agent was present in the 
loading buffer, and that polymerization would make only dimers. Through the use of an 
Innovagen peptide properties calculator (https://pepcalc.com/ ), it was revealed that the 
peptide contains a significant number of basic residues that could be preventing it from 
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properly migrating in the electrophoretic field of an acrylamide gel and could thus 
explain why all three bands from Figure 9b were visualized at 10 kD. As for solubility, 
the peptide was found to be fairly soluble in aqueous solutions. This gives it potential for 
use in the drug delivery system, and further work is necessary to functionalize the peptide 
and determine how it reacts in the presence of CMSP and calcium. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9a: MALDI-TOF of Synthetic Peptide 
Envelope of Products Revealed by MALDI Analysis: The crude sample from the peptide sample 
revealed an envelope of products ranging from 4.8 kD to 5.7 kD. The expected weight of the 
peptide was within the envelope at 5.1 kD. 
Figure 9b: Acrylamide Gel of Synthetic Peptide 
Acrylamide Gel with Reducing and Non-Reducing Loading Buffer: Samples in DMSO and 
SEC solutions with BME reducing load were visualized as bands at 10 kD. A sample in SEC 
solution with a non-reducing load was also visualized at 10 kD. 
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DISCUSSION AND CONCLUSION 
 
 
 The experiments described above indicate that our engineered PMSP construct 
has low aqueous solubility, an attribute that introduces a challenge that subverts its role 
as one of two components in an aqueous hydrogel. Below we speculate on a number of 
aspects of the experiments reported above and of the structure and function of PMSP in 
an attempt to better understand the challenges that this protein has presented. A better 
understanding of these challenges will help us to best determine the conditions for its use 
in our nascent biomaterial and will allow us to design a second generation PMSP 
protomer. 
 
Bacterial Expression of PMSP 
 
 
 There are distinct advantages to using a bacterial expression system for making 
our PMSP protomer. These expression systems are inexpensive, produce large quantities, 
and provide an inexpensive method for re-engineering the gene to improve the properties 
of the protomer. Our current system has several properties that we do not entirely 
understand.  First, in our lab, we typically store transformed expression cells as glycerol 
stocks at -80 °C. The CMSP expression cells are stored in this way, yet we have found 
that expression of PMSP is very poor in subsequent attempts after the first expression.  
We have successfully produced PMSP from the transformed cell stocks, but in low 
abundance. We have also tried an alternative cell line, and found the same phenomenon: 
after storage for one to two weeks, expression levels have dropped. Thus, to obtain 
decent yield upon expression, we must use freshly transformed cells. Interestingly, this is 
16	
	
not required of the CMSP expression cells even though the CMSP gene is identical to the 
PMSP gene except for the peptide/CaM components. There is no secondary structure 
formation that we expect in the mRNA. As of yet, we don’t have an explanation for this 
complication in the expression of PMSP. 
 
PMSP’s Insolubility 
 
 From previous experience using a 100 µM M13 stock in our lab, we have 
demonstrated that the M13 peptide is quite soluble in aqueous solutions. The PMSP 
protomer was thus designed with the belief that it would be fully soluble. Personal 
communication with Dr. Madeline Shea (University of Iowa, Department of 
Biochemistry) informed us to expect that M13 would interact with negatively charged 
phospholipids in the cell membrane during bacterial expression due to the fact that it 
contains a significant number of positively-charged, basic residues. For this reason, we 
expected that PMSP would be in the pellet fraction after sonication. We reasoned, 
however, that treatment with Triton-X would dissolve and remove the cell membrane 
lipid component, and increase the solubility of PMSP. As discussed above, PMSP 
remained insoluble after the Triton-X washes.  
Because PMSP remained in the pellet after the washes, we have been forced to 
investigate other potential issues that could be causing the lack of solubility. One 
promising possibility remains the number of collagen-like modification sequences within 
each PMSP molecule. First, the collagen-like sequences contain hydrophobic amino 
acids, no charged amino acids (GPQGIWGQ), and only two H-bond donor/acceptors. 
From this inherent hydrophobicity, it is likely that the collagen-like sequences are playing 
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a role in PMSP’s insolubility in aqueous solutions. The fact that the synthetic peptide 
with only a single collagen-like sequence demonstrated an increased solubility over 
PMSP supports this conclusion. This argument also raises the question of why the CMSP 
protomer is so soluble. One explanation is that the large hydrophilic CaM components are 
far larger than the collagen-like sequences and provide increased solubility. The 
importance of CaM in increasing the solubility of the CMSP protomer is further 
supported by the fact the PMSP protomer is only soluble in aqueous solution when in the 
presence of added CaM, as discussed above. 
Second, it is possible that the collagen-like sequences within multiple PMSP 
protomers are aggregating with one another to form the triple helix structure that 
composes collagen polymers. A brief review of the literature suggests it takes a minimum 
of 36 amino acids of collagen repeats (twelve repeats of the 3- amino acid collagen 
sequence) for the formation of collagen triple helixes 16. Because our material only 
contains 8 amino acids in each collagen-like segment, we speculate that formation of a 
full collagen triple helix is not occurring.  
 
The Role of DMSO 
 
 
 In order to work with PMSP, we needed a solvent that would solubilize our 
protomer. It was also important to find a solvent for biomaterial formation that is 
compatible with medical applications and that would be safe when administered within 
the body. We thus chose DMSO, although we are working to increase the aqueous 
solubility of the peptide construct in hopes that we will be able to work in aqueous 
solutions in the future.  
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DMSO is an amphipathic molecule with both a highly polar sulfonyl bond, and 
two non-polar methyl groups 17. It has a half-life of 16 hours within humans and can be 
administered in a number of different ways for medical applications 18. The most 
common routes of administration include topical administration to assist in drug delivery 
and via intravesical instillation in women with interstitial cystitis 19. It is important to 
note that DMSO is capable of increasing the flexibility of the phospholipid bilayer in cell 
membranes and increasing the number of water pores in the membrane 20. This property 
makes it particularly useful as a vehicle for drug delivery as it easily penetrates skin and 
other bodily barriers. Fortunately, this membrane penetration does not cause irreversible 
damage, and DMSO has been shown to have low toxicity in humans 17. This, in concert 
with the fact that DMSO itself has been directly administered as a medication, makes it 
an applicable solvent for our drug delivery system. 
 To ensure that DMSO would not prohibitively disrupt PMSP and CMSP binding, 
we conducted a brief literature review on the effect that DMSO has on general protein 
structure. The literature suggests that DMSO increasingly disrupts protein secondary 
structure as DMSO concentration increases. This occurs primarily through the disruption 
of protein hydrogen bonding networks 21. In pure DMSO, it was found that a majority of 
proteins are almost completely unfolded and tend to form aggregates. Our data with 
CMSP and PMSP forming a turbid material in DMSO suggests that the two protomers 
are still cable of binding when in the presence of extraordinarily high concentrations of 
calcium. We speculate that the high levels of calcium drive the maintenance of secondary 
structure within the highly resilient CMSP and allow it to bind PMSP, which is already 
unstructured. It will be necessary to conduct further binding studies between CaM and 
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M13 and between PMSP and CMSP in DMSO to determine the optimum conditions for 
binding. In theory, these speculations should be testable, but since DMSO has a large 
absorbance in the region of the spectrum in which secondary structures absorb light, we 
cannot use instrumentation routinely available to us. We are actively working on using 
fluorescence to monitor the environment of the tryptophan residues as a function of CaM 
binding and solvent composition. 
 
Implications and Direction for Future Research 
 
 
 At this time, the CMSP component is fully functional and behaves as expected 
(soluble and demonstrates calcium-dependent M13 binding). It will thus be important to 
continue to study PMSP in DMSO, work to increase its aqueous solubility, and to 
characterize the formation of gels. One promising alternative remains to design a gene 
that contains only a single collagen-like modification sequence to increase the 
hydrophilic/hydrophobic ratio of the protein. In addition, it will be important to further 
investigate the gelatinous material that was removed in Figure 6b and to confirm the 
increase in viscosity observed in Figure 8c through the use of rheometry. Furthermore, it 
will be necessary to assess the susceptibility of the components to degradation by 
proteases that will be present in the extracellular matrix.  In conclusion, both protomers 
have shown promise as a means to create a novel in-situ delivery system.  
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APPENDIX 
 
 
 
Appendix 1: Full Amino Acid Sequence of PMSP Protomer: This schematic 
provides the full AA sequence for our protomer. The 6 histidine histag sequence is 
underlined. In bold, the 28 AA sequence for the M13 peptide. The collagen-like 
modification sequences are shown in boxes. Finally, the terminal cysteine is shown 
in red. 
